Acupuncture Ranks High ‘High’ on List of Options Kidney Cancer Pain Management

Video

Massage and acupuncture represent promising integrative care strategies for managing stress and pain in patients with kidney cancer and other tumors, according to an expert from University Hospitals.

During Kidney Cancer Awareness Month 2023, CancerNetwork® spoke with Santosh Rao, MD, about common integrative care techniques that have helped with managing symptoms associated with kidney cancer and treatment including pain and that are used at his institution.

According to Rao, medical director of integrative oncology for University Hospitals Connor Whole Health and president-elect for the Society for Integrative Oncology, acupuncture in particular has demonstrated benefits in terms of alleviating pain, neuropathy, joint aches, and hot flashes.

Rao also spoke about other strategies including managing a patient’s diet and exercise routines to reduce the chances of disease recurrence.

Transcript:

When I think of integrative oncology, I think of a couple of different things. For people where we’re trying to reduce chances of recurrences—that often [involves] lifestyle strategies—that can be important when somebody has been diagnosed and is going through treatment, although it’s often very important afterwards, as well. And that [involves] diet, exercise, and stress management, primarily.

The other side of it is “How can we alleviate symptoms and reduce toxicity from treatments?” And that’s where things like acupuncture really come into play [along with] massage and stress management. We know all of these techniques that all help with a variety of symptoms, including pain and anxiety. There’s different evidence for each one. Neuropathy is something that we see a lot with chemotherapy, for example. How can we reduce some of those symptoms?

I found acupuncture is high on the list when it comes to pain, neuropathy, hot flashes, and joint aches. Massage can be very helpful as well for stress management; we’ve seen in some studies [that it] improves pain and anxiety. And then you want to personalize these approaches to what the patient would benefit from the most and maybe what their interests are, which is partly based on cultural aspects and past experiences. You have to tailor the approach based on what we have available, and what you think will help for those specific symptoms.

Recent Videos
“This is something where this is written by the trainees, for the trainees, and, of course, for all the other clinicians who take care of patients,” said Kiran Turaga, MD, MPH.
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
Osimertinib/chemotherapy and amivantamab/lazertinib have exhibited an efficacy advantage vs osimertinib in patients with EGFR-mutant NSCLC.
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Related Content